By now, it should be news to no one that Wall Street analysts were hopeless romantics in the 1990s. Smitten with tech-stock love, they fell head over heels for unrealistic growth expectations, "eyeball"-based business models, and all things dot-com.
When the bubble burst in early 2000, these love-struck analysts were caught with their analytical pants down. As tech stocks plunged from stratosphere to lithosphere, a whopping 95% of all equity issues then trading on the public markets were totally free of any "sell" ratings. What's more, according to investment research firm Zacks, the 5% of stocks that did have a sell rating had exactly that: one sell rating. Every analyst in the country, with the exception of a lone crank, refused to cast doubt on these most doubtfully priced of companies.
And then what happened?
- Oracle (NASDAQ:ORCL): down 71%.
- Cree (NASDAQ:CREE): down 87%.
- Infospace (NASDAQ:INSP): down 98%.
Things change yet remain the same
After the bubble's "pop," a new trend emerged. Stock analysts began to reverse themselves, advising investors to sell what was left of their stocks.
And so the stocks began to rise.
In fact, in every single year of the new millennium, stocks rated "sell" by Wall Street have outperformed stocks rated "buy" or "hold." Over the past four years, stocks that the Street has been telling you to sell have risen 19% per annum on average. Meanwhile, the "buys" and "holds" have risen just 7%.
So is Wall Street just stupid?
No. On the contrary, the analysts working on the Street are pretty bright guys -- but that doesn't necessarily work to your advantage.
You see, just because a sell-side analyst believes a stock is a dud, that doesn't necessarily mean he's going to clue you in to this fact. Think back to that 2002 TV ad from Charles Schwab, where the pinstriped broker tells his analyst: "Let's put some lipstick on this pig!" That's how the game was played pre-millennium. Analysts might have had private reservations -- heck, they might have had a private case of the giggles -- about the prospects for a stock. But that certainly didn't mean they were going to rate it a "sell."
Remember, these people have commissions to earn. And they don't make commissions by telling people who don't own a stock that they shouldn't own it. They make commissions by telling people who don't own a stock that they need to buy one right now.
And of course, if their private belief that the company is doomed turns out to be right, there's plenty of time down the road to make a second commission by opining that the circumstances have now changed, and it's time to sell that stock that they told you to buy three months ago.
Gurus gone mild
But the desire to make sales and earn commissions is only half the story. The other reason that Wall Street analysts tend to make bad calls in public -- even when they're right in private -- derives from the fact that they are (not to put too fine a point on it) a bunch of desk-bound, paycheck-driven bureaucrats.
Try to look at life from the other side of the analyst's desk for a moment, and you'll see what I'm getting at. Let's say that five years ago, an analyst had to make a decision between recommending "engine-of-the-future" inventor Ballard (NASDAQ:BLDP), or technical ceramic products-maker Ceradyne (NASDAQ:CRDN) -- a stock that hadn't gained a penny in value over the past four years. It was a basket case of a business spurned by most of Wall Street.
At the time, few people suspected that the next five years would see Ballard lose 95% of its market cap, while Ceradyne turned into a six-bagger. And of those analysts who did see the impending need for ceramic-plated body armor, few were willing to bet their jobs on it.
Herd mentality
To see why that's so, let's turn for a moment to legendary investor and former head of the Fidelity Magellan Fund Peter Lynch. He summed up Wall Street analysts' thinking on questions such as the Ballard/Ceradyne dilemma thusly: "Success is one thing, but it's more important not to look bad if you fail."
Sure, an analyst could have made his clients a lot of money by seeing the value inside Ceradyne, the potential for outsized returns just waiting to be unlocked. But what if the analyst was wrong? When all of your colleagues are pointing out a company's problems, do you go out on a limb and say: "I beg to differ?" Probably not. Because if you're wrong, you'll be begging, all right -- begging for your job.
Now contrast that with what happens when an analyst puts a "buy" recommendation on a stock such as Genentech (NYSE:DNA) -- a company that currently sports 20 "buys" and 10 "holds," but not a single "sell." If everyone is sure that a stock will go up, and it does, it's all good. On the other hand, if the stock somehow tanks, everyone just gasps in mock amazement: "Wow. Genentech really made a mess of things."
See the change in emphasis? If an analyst's right in a crowd, he's just right. But if he's wrong in a crowd, the analyst -- and everyone else who was wrong along with him -- chants in unison: "We didn't do anything wrong. The company screwed up."
Thus, analysts have learned that there's safety in numbers. It's the cow that wanders from the herd that gets eaten by wolves (or thrown to them by an irate mutual fund manager). But as long as the analyst sticks with the rest of the cattle, it doesn't much matter whether the herd's moving in the right direction or the wrong one -- the analyst's job is safe.
Be the cowboy, not the cow
As an individual investor, however, you don't have to be part of the herd. Like a cowboy circling on the outside, you can watch as the cows shamble to and fro, yet move independently yourself. When the analysts are all chanting "buy, buy" and charging toward a cliff, you can just step out of the way. And when they're bellowing "sell, sell" and rushing off to greener pastures on the other side of some fence, you can wait until they're gone and examine what they're leaving behind. Could be that you'll find it right tasty.
Now mind you, any pasture that the analyst herd is so eager to leave is probably laden with certain, er, landmines. So you do want to watch your step as you go a-grazing. That's where our research team at the Motley Fool Inside Value newsletter service can help. They're adept at picking their way through well-used fields of abandoned stocks, locating and avoiding the landmines, and finding tasty treats such as recent Inside Value pick Omnicare (NYSE:OCR), which rose 67% in less than a year after it was chosen. In fact, since the newsletter first began publishing one year ago, it has already found nearly two dozen such winning stocks for subscribers.
For a peek at the treasures Inside Value has already turned up, join us for a free one-month trial by clicking here. Or, even better, subscribe and receive -- for free -- a copy of The Motley Fool's Blue-Chip Report 2005: 10 Monster Stocks for the Next Decade. Click here to learn more.
This article was originally published on April 28, 2005. It has been updated.
Fool contributor Rich Smith has no financial position in any of the companies mentioned in this article. The value of The Motley Fool's disclosure policy is a definite "buy."
